1
|
Aveyard L, Murray FJ, Hubbard SA, Hoberman AM, Allen BC, Carey S. OECD 414 supplementary prenatal developmental toxicity study of sodium molybdate dihydrate in the rat and benchmark dose evaluation. Reprod Toxicol 2023; 120:108443. [PMID: 37473931 DOI: 10.1016/j.reprotox.2023.108443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2023] [Revised: 07/14/2023] [Accepted: 07/17/2023] [Indexed: 07/22/2023]
Abstract
In a continuing investigation of the potential for reproductive and developmental toxicity of molybdenum (Mo), consequent to the previous published OECD studies [1,2] and as directed by the European Chemicals Agency [3], a supplemental rat GLP-compliant Prenatal Developmental Toxicity (PNDT) study was conducted to investigate higher dose levels of sodium molybdate dihydrate (SMD) in an identical study design (OECD 414)[4] to Murray et al. 2014a [1], at dietary concentrations calculated to provide target Mo levels of 80 and 120 mg/kg bw/day (the maximum-tolerated dose). There was no effect on post-implantation loss, litter size, sex ratio or the incidence of external, visceral or skeletal fetal malformations or variations. Fetal weight was reduced proportionate to maternal dose. Minimal differences observed in the ossification status of some extremities of fetuses from females receiving 120 mg Mo/kg bw/day were confirmed as transient by skeletal examination of PND 21 pups from a further group of females receiving the same dose regime. There was no evidence of copper depletion in serum, placenta or liver. A benchmark dose evaluation using continuous and dichotomous approaches by combining the fetal body weight data from this study and the previous study determined that the BMD05 ranged from 47 to 57 mg Mo/kg bw/day, depending on the modelling approach and the BMDL05 estimates ranged from 37 to 47 mg Mo/kg bw/day. These levels are considered a more statistically robust point of departure for risk assessment for reproductive effects than the established NOAEL of 40 mg Mo/kg bw/day.
Collapse
Affiliation(s)
| | | | | | - A M Hoberman
- Charles River Laboratories, Inc., Horsham, PA, USA
| | - B C Allen
- Independent Consultant, Carrboro, NC, USA
| | - S Carey
- International Molybdenum Association, 523 Avenue Louise, 1050 Brussels, Belgium.
| |
Collapse
|
2
|
Ramalho CEL, Reis DDS, Caixeta GAB, Oliveira MCD, Silva DMFD, Cruvinel WDM, Teófilo MNG, Gomes CM, Sousa PAD, Soares LF, Melo AMD, Rocha JD, Bailão EFLC, Amaral VCS, Paula JAMD. Genotoxicity and maternal-fetal safety of the dried extract of leaves of Azadirachta indica A. Juss (Meliaceae) in Wistar rats. JOURNAL OF ETHNOPHARMACOLOGY 2023; 310:116403. [PMID: 36963474 DOI: 10.1016/j.jep.2023.116403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 03/07/2023] [Accepted: 03/17/2023] [Indexed: 06/18/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Azadirachta indica A. Juss (Meliaceae), popularly known as "neem", is used for the treatment of rheumatism, cancer, ulcers, diabetes, respiratory problems, among others. This species is present on six continents and contains more than 400 bioactive compounds. Practically all parts of the plant are used in the treatment of diseases. Although it is widely used, no study has evaluated the safety of this species throughout the gestational period in Wistar rats. AIM OF THE STUDY To evaluate the genotoxicity and the effect of treatment with dried extract of leaves of Azadirachta indica on maternal toxicity and fetal development. MATERIALS AND METHODS The dried extract of leaves of A. indica was obtained by spray drying after percolation of the plant material in 30% ethanol (w/w). The total flavonoids and rutin contents of the extract were determined by spectrophotometric method and HPLC-DAD, respectively. Pregnant Wistar rats (n = 40) were divided into four groups (n = 10/group): one control and three groups treated with dried extract of leaves of A. indica at doses of 300, 600 or 1200 mg/kg. Treatments were carried out from gestational day (GD) 0-20. During gestation, clinical signs of toxicity, weight gain, feed and water consumption of the dams were evaluated. On GD 21, rats were euthanized and cardiac blood was collected. Liver, kidneys, lung, heart, uterus, ovaries and bone marrow were collected. Reproductive performance parameters, histopathological analysis, biochemistry and genotoxicity were evaluated. Fetuses were evaluated for external morphology, skeletal and visceral changes. RESULTS The total flavonoid content of the extract ranged from 2.64 to 3.01%, and the rutin content was 1.07%. There was no change in body mass gain, food and water consumption between the evaluated groups. There was also no difference between the groups in terms of biochemical parameters, reproductive performance, histopathological analysis of the mother's organs and genotoxicity. Supernumerary ossification sites of the sternum were observed, and other skeletal and visceral alterations were not significant. CONCLUSIONS The treatment did not induce maternal toxicity, it was neither embryotoxic nor fetotoxic. The extract was not potentially genotoxic, and at a dose of 1200 mg/kg, it caused changes in the ossification of the sternum.
Collapse
Affiliation(s)
- Carlos Eduardo Lacerda Ramalho
- Programa de Pós-Graduação em Ciências Aplicadas a Produtos para Saúde (CAPS). Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil; Laboratório de Pesquisa, Desenvolvimento & Inovação de Produtos da Biodiversidade. Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil
| | - Diego Dos Santos Reis
- Laboratório de Farmacologia e Toxicologia de Produtos Naturais e Sintéticos. Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil
| | - Graziele Alícia Batista Caixeta
- Programa de Pós-Graduação em Ciências Aplicadas a Produtos para Saúde (CAPS). Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil; Laboratório de Farmacologia e Toxicologia de Produtos Naturais e Sintéticos. Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil
| | - Micaelle Cristina de Oliveira
- Laboratório de Farmacologia e Toxicologia de Produtos Naturais e Sintéticos. Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil
| | - Danielle Milany Fernandes da Silva
- Laboratório de Farmacologia e Toxicologia de Produtos Naturais e Sintéticos. Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil
| | - Wilson de Melo Cruvinel
- Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás, Goiânia, Goiás, Brazil
| | | | - Clayson Moura Gomes
- Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás, Goiânia, Goiás, Brazil
| | | | - Leiza Fagundes Soares
- Programa de Pós-Graduação em Ciências Aplicadas a Produtos para Saúde (CAPS). Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil; Laboratório de Pesquisa, Desenvolvimento & Inovação de Produtos da Biodiversidade. Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil
| | - Anielly Monteiro de Melo
- Laboratório de Pesquisa, Desenvolvimento & Inovação de Produtos da Biodiversidade. Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil
| | - Jamira Dias Rocha
- Laboratório de Biotecnologia. Universidade Estadual de Goiás, Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil
| | - Elisa Flávia Luiz Cardoso Bailão
- Laboratório de Biotecnologia. Universidade Estadual de Goiás, Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil
| | - Vanessa Cristiane Santana Amaral
- Programa de Pós-Graduação em Ciências Aplicadas a Produtos para Saúde (CAPS). Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil; Laboratório de Farmacologia e Toxicologia de Produtos Naturais e Sintéticos. Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil
| | - Joelma Abadia Marciano de Paula
- Programa de Pós-Graduação em Ciências Aplicadas a Produtos para Saúde (CAPS). Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil; Laboratório de Pesquisa, Desenvolvimento & Inovação de Produtos da Biodiversidade. Universidade Estadual de Goiás. Campus Anápolis de Ciências Exatas e Tecnológicas, Anápolis, Goiás, Brazil.
| |
Collapse
|
3
|
DeSesso JM, Scialli AR. Bone development in laboratory mammals used in developmental toxicity studies. Birth Defects Res 2018; 110:1157-1187. [PMID: 29921029 DOI: 10.1002/bdr2.1350] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 04/19/2018] [Accepted: 04/25/2018] [Indexed: 01/12/2023]
Abstract
Evaluation of the skeleton in laboratory animals is a standard component of developmental toxicology testing. Standard methods of performing the evaluation have been established, and modification of the evaluation using imaging technologies is under development. The embryology of the rodent, rabbit, and primate skeleton has been characterized in detail and summarized herein. The rich literature on variations and malformations in skeletal development that can occur in the offspring of normal animals and animals exposed to test articles in toxicology studies is reviewed. These perturbations of skeletal development include ossification delays, alterations in number, shape, and size of ossification centers, and alterations in numbers of ribs and vertebrae. Because the skeleton is undergoing developmental changes at the time fetuses are evaluated in most study designs, transient delays in development can produce apparent findings of abnormal skeletal structure. The determination of whether a finding represents a permanent change in embryo development with adverse consequences for the organism is important in study interpretation. Knowledge of embryological processes and schedules can assist in interpretation of skeletal findings.
Collapse
|
4
|
Fowles J, Banton M, Klapacz J, Shen H. A toxicological review of the ethylene glycol series: Commonalities and differences in toxicity and modes of action. Toxicol Lett 2017; 278:66-83. [PMID: 28689762 DOI: 10.1016/j.toxlet.2017.06.009] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2017] [Revised: 05/23/2017] [Accepted: 06/21/2017] [Indexed: 11/27/2022]
Abstract
This review summarizes the hazards, exposure and risk that are associated with ethylene glycols (EGs) in their intended applications. Ethylene glycol (EG; CAS RN 107-21-1) and its related oligomers include mono-, di-, tri-, tetra-, and penta-EG. All of the EGs are quickly and extensively absorbed following ingestion and inhalation, but not by the dermal route. Metabolism involves oxidation to the mono- and dicarboxylic acids. Elimination is primarily through the urine as the parent compound or the monoacid, and, in the case of EG, also as exhaled carbon dioxide. All EGs exert acute toxicity in a similar manner, characterized by CNS depression and metabolic acidosis in humans and rodents; the larger molecules being proportionally less acutely toxic on a strict mg/kg basis. Species differences exist in the metabolism and distribution of toxic metabolites, particularly with the formation of glycolic acids and oxalates (OX) from EG and diethylene glycol (DEG); OX are not formed to a significant degree in higher ethylene glycols. Among rodents, rats are more sensitive than mice, and males more sensitive than females to the acute and repeated-dose toxicity of EG. The metabolic formation of glycolic acid (GA), diglycolic acid (DGA), and OX are associated with nephrotoxicity in humans and rodents following single and repeated exposures. However, physiological and metabolic differences in the rate of formation of GA, DGA and OX and their distribution result in EG and DEG causing embryotoxicity in rats, but not rabbits. This rodent-specific sensitivity indicates that EG and its higher oligomers are not anticipated to be embryotoxic in humans at environmentally relevant doses. None of the compounds present developmental toxicity concerns at doses that do not also cause significant maternal toxicity, nor do any of the EGs cause adverse effects on fertility. The EGs are neither genotoxic nor carcinogenic. A read-across matrix is presented, which considers the common and distinct toxicological properties of each compound. It is concluded that EGs pose no risk to human health as a result of their intended use patterns.
Collapse
Affiliation(s)
| | | | | | - Hua Shen
- Shell Oil Company, Houston, TX, USA
| |
Collapse
|
5
|
Moore NP, Boogaard PJ, Bremer S, Buesen R, Edwards J, Fraysse B, Hallmark N, Hemming H, Langrand-Lerche C, McKee RH, Meisters ML, Parsons P, Politano V, Reader S, Ridgway P, Hennes C. Guidance on classification for reproductive toxicity under the globally harmonized system of classification and labelling of chemicals (GHS). Crit Rev Toxicol 2014; 43:850-91. [PMID: 24274377 DOI: 10.3109/10408444.2013.854734] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The Globally Harmonised System of Classification (GHS) is a framework within which the intrinsic hazards of substances may be determined and communicated. It is not a legislative instrument per se, but is enacted into national legislation with the appropriate legislative instruments. GHS covers many aspects of effects upon health and the environment, including adverse effects upon sexual function and fertility or on development. Classification for these effects is based upon observations in humans or from properly designed experiments in animals, although only the latter is covered herein. The decision to classify a substance based upon experimental data, and the category of classification ascribed, is determined by the level of evidence that is available for an adverse effect on sexual function and fertility or on development that does not arise as a secondary non-specific consequence of other toxic effect. This document offers guidance on the determination of level of concern as a measure of adversity, and the level of evidence to ascribe classification based on data from tests in laboratory animals.
Collapse
|